CVS Caremark Value Formulary Effective as of 10/01/2019

CVS Caremark? Value Formulary Effective as of 01/01/2022

Value Formulary

01/01/2022

INTRODUCTION....................................................................................................................................................................................................... 4

PREFACE ................................................................................................................................................................................................................. 4

PHARMACY AND THERAPEUTICS (P&T) COMMITTEE ...................................................................................................................................... 4

DRUG LIST PRODUCT DESCRIPTIONS................................................................................................................................................................ 5

GENERIC SUBSTITUTION ...................................................................................................................................................................................... 5

SPECIALTY MEDICATIONS.................................................................................................................................................................................... 6

PLAN DESIGN.......................................................................................................................................................................................................... 6

PREVENTIVE SERVICES ........................................................................................................................................................................................ 7

LEGEND ................................................................................................................................................................................................................... 7

NOTICE..................................................................................................................................................................................................................... 8

ANALGESICS........................................................................................................................................................................................................... 9 NSAIDs........................................................................................................................................................................................................... 9 GOUT ............................................................................................................................................................................................................. 9 OPIOID ANALGESICS ................................................................................................................................................................................... 9 VISCOSUPPLEMENTS ............................................................................................................................................................................... 10

ANTI-INFECTIVES ................................................................................................................................................................................................. 10 ANTIBACTERIALS ....................................................................................................................................................................................... 10 ANTIFUNGALS ............................................................................................................................................................................................ 11 ANTIRETROVIRAL AGENTS ...................................................................................................................................................................... 11 ANTITUBERCULAR AGENTS ..................................................................................................................................................................... 12 ANTIVIRALS................................................................................................................................................................................................. 13 MISCELLANEOUS ....................................................................................................................................................................................... 13

ANTINEOPLASTIC AGENTS ................................................................................................................................................................................ 14 ALKYLATING AGENTS ............................................................................................................................................................................... 14 ANTIMETABOLITES .................................................................................................................................................................................... 14 BIOSIMILARS............................................................................................................................................................................................... 14 HORMONAL ANTINEOPLASTIC AGENTS................................................................................................................................................. 14 KINASE INHIBITORS................................................................................................................................................................................... 15 MULTIPLE MYELOMA ................................................................................................................................................................................. 15 PROSTATE CANCER .................................................................................................................................................................................. 15 MISCELLANEOUS ....................................................................................................................................................................................... 16

CARDIOVASCULAR .............................................................................................................................................................................................. 16 ACE INHIBITORS......................................................................................................................................................................................... 16 ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS ........................................................................................................ 16 ACE INHIBITOR/DIURETIC COMBINATIONS ............................................................................................................................................ 16 ADRENOLYTICS, CENTRAL....................................................................................................................................................................... 16 ALDOSTERONE RECEPTOR ANTAGONISTS .......................................................................................................................................... 17 ANGIOTENSIN II RECEPTOR ANTAGONISTS/DIURETIC COMBINATIONS........................................................................................... 17 ANGIOTENSIN II RECEPTOR ANTAGONIST/CALCIUM CHANNEL BLOCKER COMBINATIONS ......................................................... 17 ANTIARRHYTHMICS ................................................................................................................................................................................... 17 ANTILIPEMICS............................................................................................................................................................................................. 17 BETA-BLOCKERS ....................................................................................................................................................................................... 18 BETA-BLOCKER/DIURETIC COMBINATIONS........................................................................................................................................... 18 CALCIUM CHANNEL BLOCKERS .............................................................................................................................................................. 18 DIGITALIS GLYCOSIDES............................................................................................................................................................................ 19 DIURETICS .................................................................................................................................................................................................. 19 HEART FAILURE ......................................................................................................................................................................................... 19 NITRATES.................................................................................................................................................................................................... 19 PULMONARY ARTERIAL HYPERTENSION .............................................................................................................................................. 19 MISCELLANEOUS ....................................................................................................................................................................................... 20

CENTRAL NERVOUS SYSTEM ............................................................................................................................................................................ 20 ANTIANXIETY .............................................................................................................................................................................................. 20

?2021 CVS Health and/or one of its affiliates. All rights reserved. 106-25954B 010122 1

ANTICONVULSANTS .................................................................................................................................................................................. 20 ANTIDEMENTIA........................................................................................................................................................................................... 21 ANTIDEPRESSANTS .................................................................................................................................................................................. 21 ANTIPARKINSONIAN AGENTS .................................................................................................................................................................. 22 ANTIPSYCHOTICS ...................................................................................................................................................................................... 22 ATTENTION DEFICIT HYPERACTIVITY DISORDER ................................................................................................................................ 23 FIBROMYALGIA........................................................................................................................................................................................... 23 HYPNOTICS................................................................................................................................................................................................. 23 MIGRAINE.................................................................................................................................................................................................... 23 MOOD STABILIZERS .................................................................................................................................................................................. 24 MOVEMENT DISORDERS .......................................................................................................................................................................... 24 MULTIPLE SCLEROSIS AGENTS .............................................................................................................................................................. 24 MUSCULOSKELETAL THERAPY AGENTS ............................................................................................................................................... 24 MYASTHENIA GRAVIS ............................................................................................................................................................................... 24 NARCOLEPSY ............................................................................................................................................................................................. 24 PSYCHOTHERAPEUTIC-MISCELLANEOUS ............................................................................................................................................. 24 MISCELLANEOUS ....................................................................................................................................................................................... 25

ENDOCRINE AND METABOLIC ........................................................................................................................................................................... 25 ACROMEGALY ............................................................................................................................................................................................ 25 ANDROGENS .............................................................................................................................................................................................. 25 ANTIDIABETICS .......................................................................................................................................................................................... 25 ANTIOBESITY.............................................................................................................................................................................................. 27 CALCIUM RECEPTOR ANTAGONISTS ..................................................................................................................................................... 27 CALCIUM REGULATORS ........................................................................................................................................................................... 27 CENTRAL PRECOCIOUS PUBERTY ......................................................................................................................................................... 27 CONTRACEPTIVES .................................................................................................................................................................................... 27 ENDOMETRIOSIS ....................................................................................................................................................................................... 29 FERTILITY REGULATORS.......................................................................................................................................................................... 29 GAUCHER DISEASE ................................................................................................................................................................................... 29 GLUCOCORTICOIDS .................................................................................................................................................................................. 29 GLUCOSE ELEVATING AGENTS............................................................................................................................................................... 29 HEREDITARY TYROSINEMIA TYPE 1 AGENTS ....................................................................................................................................... 29 HUMAN GROWTH HORMONES................................................................................................................................................................. 29 HYPERPARATHYROID TREATMENT, VITAMIN D ANALOGS ................................................................................................................. 29 MENOPAUSAL SYMPTOM AGENTS ......................................................................................................................................................... 29 PHENYLKETONURIA TREATMENT AGENTS ........................................................................................................................................... 30 PHOSPHATE BINDER AGENTS................................................................................................................................................................. 30 POLYNEUROPATHY ................................................................................................................................................................................... 30 POTASSIUM-REMOVING AGENTS............................................................................................................................................................ 30 PROGESTINS .............................................................................................................................................................................................. 30 SELECTIVE ESTROGEN RECEPTOR MODULATORS............................................................................................................................. 30 THYROID AGENTS ..................................................................................................................................................................................... 30 UREA CYCLE DISORDERS ........................................................................................................................................................................ 30 VASOPRESSINS ......................................................................................................................................................................................... 31 MISCELLANEOUS ....................................................................................................................................................................................... 31

GASTROINTESTINAL ........................................................................................................................................................................................... 31 ANTIDIARRHEALS ...................................................................................................................................................................................... 31 ANTIEMETICS ............................................................................................................................................................................................. 31 ANTISPASMODICS ..................................................................................................................................................................................... 31 CHOLELITHOLYTICS .................................................................................................................................................................................. 31 H2 RECEPTOR ANTAGONISTS.................................................................................................................................................................. 31 INFLAMMATORY BOWEL DISEASE .......................................................................................................................................................... 31 IRRITABLE BOWEL SYNDROME ............................................................................................................................................................... 32 LAXATIVES .................................................................................................................................................................................................. 32 OPIOID-INDUCED CONSTIPATION ........................................................................................................................................................... 32 PANCREATIC ENZYMES............................................................................................................................................................................ 32 PROSTAGLANDINS .................................................................................................................................................................................... 32 PROTON PUMP INHIBITORS ..................................................................................................................................................................... 32 SALIVA STIMULANTS ................................................................................................................................................................................. 32 STEROIDS, RECTAL ................................................................................................................................................................................... 32 MISCELLANEOUS ....................................................................................................................................................................................... 32

?2021 CVS Health and/or one of its affiliates. All rights reserved. 106-25954B 010122 2

GENITOURINARY .................................................................................................................................................................................................. 32 BENIGN PROSTATIC HYPERPLASIA ........................................................................................................................................................ 32 URINARY ANTISPASMODICS .................................................................................................................................................................... 32 VAGINAL ANTI-INFECTIVES ...................................................................................................................................................................... 33 MISCELLANEOUS ....................................................................................................................................................................................... 33

HEMATOLOGIC ..................................................................................................................................................................................................... 33 ANTICOAGULANTS .................................................................................................................................................................................... 33 CHELATING AGENTS ................................................................................................................................................................................. 33 HEMATOPOIETIC GROWTH FACTORS .................................................................................................................................................... 33 HEMOPHILIA A AGENTS ............................................................................................................................................................................ 33 HEMOPHILIA B AGENTS ............................................................................................................................................................................ 33 MISCELLANEOUS BLEEDING DISORDERS AGENTS ............................................................................................................................. 34 PLATELET AGGREGATION INHIBITORS.................................................................................................................................................. 34 PLATELET SYNTHESIS INHIBITORS ........................................................................................................................................................ 34 THROMBOCYTOPENIA AGENTS .............................................................................................................................................................. 34 MISCELLANEOUS ....................................................................................................................................................................................... 34

IMMUNOLOGIC AGENTS...................................................................................................................................................................................... 34 ALLERGENIC EXTRACTS .......................................................................................................................................................................... 34 AUTOIMMUNE AGENTS (PHYSICIAN-ADMINISTERED).......................................................................................................................... 34 AUTOIMMUNE AGENTS (SELF-ADMINISTERED) .................................................................................................................................... 34 DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs) ................................................................................................................. 35 HEREDITARY ANGIOEDEMA AGENTS ..................................................................................................................................................... 35 IMMUNOMODULATORS ............................................................................................................................................................................. 35 IMMUNOSUPPRESSANTS ......................................................................................................................................................................... 35

NUTRITIONAL/SUPPLEMENTS............................................................................................................................................................................ 36 ELECTROLYTES ......................................................................................................................................................................................... 36 VITAMINS AND MINERALS ........................................................................................................................................................................ 36

RESPIRATORY ...................................................................................................................................................................................................... 36 ALPHA-1 ANTITRYPSIN DEFICIENCY AGENTS ....................................................................................................................................... 36 ANAPHYLAXIS TREATMENT AGENTS ..................................................................................................................................................... 36 ANTICHOLINERGICS .................................................................................................................................................................................. 37 ANTICHOLINERGIC/BETA AGONIST COMBINATIONS............................................................................................................................ 37 ANTIHISTAMINES, SEDATING................................................................................................................................................................... 37 ANTITUSSIVES............................................................................................................................................................................................ 37 ANTITUSSIVE COMBINATIONS ................................................................................................................................................................. 37 BETA AGONISTS ........................................................................................................................................................................................ 37 CYSTIC FIBROSIS ...................................................................................................................................................................................... 37 LEUKOTRIENE MODULATORS.................................................................................................................................................................. 38 NASAL ANTIHISTAMINES .......................................................................................................................................................................... 38 NASAL STEROIDS ...................................................................................................................................................................................... 38 PULMONARY FIBROSIS AGENTS ............................................................................................................................................................. 38 SEVERE ASTHMA AGENTS ....................................................................................................................................................................... 38 STEROID/BETA AGONIST COMBINATIONS ............................................................................................................................................. 38 STEROID INHALANTS ................................................................................................................................................................................ 38 XANTHINES ................................................................................................................................................................................................. 38 MISCELLANEOUS ....................................................................................................................................................................................... 38

TOPICAL ................................................................................................................................................................................................................ 38 DERMATOLOGY.......................................................................................................................................................................................... 38 MOUTH/THROAT/DENTAL AGENTS ......................................................................................................................................................... 40 OPHTHALMIC .............................................................................................................................................................................................. 41 OTIC ............................................................................................................................................................................................................. 42

WEBSITES ............................................................................................................................................................................................................. 43

INDEX ..................................................................................................................................................................................................................... 45

?2021 CVS Health and/or one of its affiliates. All rights reserved. 106-25954B 010122 3

INTRODUCTION

We are pleased to provide the 2022 Value Formulary as a useful reference and informational tool. This document can assist practitioners in selecting clinically appropriate and cost-effective products for their patients.

The drugs represented have been reviewed by a National Pharmacy and Therapeutics (P&T) Committee and are approved for inclusion. The document is reflective of current medical practice as of the date of review.

The information contained in this document and its appendices is provided solely for the convenience of medical providers. We do not warrant or assure accuracy of such information nor is it intended to be comprehensive in nature. This document is not intended to be a substitute for the knowledge, expertise, skill and judgment of the medical provider in his or her choice of prescription drugs. All the information in the document is provided as a reference for drug therapy selection. Specific drug selection for an individual patient rests solely with the prescriber.

The document is subject to state-specific regulations and rules, including, but not limited to, those regarding generic substitution, controlled substance schedules, preference for brands and mandatory generics whenever applicable.

We assume no responsibility for the actions or omissions of any medical provider based upon reliance, in whole or in part, on the information contained herein. The medical provider should consult the drug manufacturer's product literature or standard references for more detailed information.

National guidelines can be found on the National Guideline Clearinghouse site at , on the websites listed under each therapeutic class and on the sites listed in the Websites section of this publication.

PREFACE

The document is organized by sections. Each section is divided by therapeutic drug class primarily defined by mechanism of action. Products are listed by generic name with brand name for reference only. Unless the cited drug is available as an injectable or an exception is specifically noted, generally, all applicable dosage forms and strengths of the drug cited are included in the document.

Drugs represented in this document may have varying cost to the plan member based on the plan's benefit structure. Some prescription benefit plan designs may alter coverage of certain products or vary copay amounts based on the condition being treated. Generic medications typically are available at the lower cost, brand-name medications on the document will generally cost more than generics. Generics should be considered the first line of prescribing subject to applicable rules.

PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

The services of an independent National Pharmacy and Therapeutics Committee ("P&T Committee") are utilized to approve safe and clinically effective drug therapies. The P&T Committee is an external advisory body of clinical professionals from across the United States. The P&T Committee's voting members include physicians, pharmacists, a pharmacoeconomist and a medical ethicist, all of whom have a broad background of clinical and academic expertise regarding prescription drugs. Employees with significant clinical expertise are invited to meet with the P&T Committee, but no CVS Caremark employee may vote on issues before the P&T Committee. Voting members of the P&T Committee must disclose any financial relationship or conflicts of interest with any pharmaceutical manufacturers.

?2021 CVS Health and/or one of its affiliates. All rights reserved. 106-25954B 010122 4

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download